Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAUR-101
- Development stage
- Preclinical
- Lead developer
- Lauren Sciences
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
**LAUR-101** is a preclinical intravenous nanomedicine from Lauren Sciences being developed for Parkinson's disease. It uses the company's V-Smart nanoparticle platform to deliver **glial cell-derived neurotrophic factor** across the blood-brain barrier to dopaminergic neurons in the striatum and substantia nigra, with the goal of providing neurotrophic support and slowing neurodegeneration. The therapeutic payload is GDNF, a protein that signals through the GFRalpha1 and RET pathway and has shown neuroprotective and dopaminergic-restorative effects in preclinical Parkinson's disease models; Lauren Sciences has reported animal data indicating brain delivery after IV dosing, improved motor outcomes, increased dopamine levels, and preservation of dopaminergic neurons.
- Other names
- GDNF V-Smart nanomedicine
02
Targets
GFRA1 (Glial cell line-derived neurotrophic factor family receptor alpha 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on LAUR-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LAUR-101.